^
HRD
|
Pancreatic Cancer
|
HRD
|
Pancreatic Cancer
|
ABT-888 Resistant: C4 – Case Studies
Clin Cancer Res - 3 weeks
|
ABT-888 Resistant: C4 – Case Studies
Clin Cancer Res - 3 weeks
|
BRCA2 mutation
|
Pancreatic Cancer
|
BRCA2 mutation
|
Pancreatic Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
BRCA1 mutation
|
Pancreatic Cancer
|
BRCA1 mutation
|
Pancreatic Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
No biomarker
|
Pancreatic Adenocarcinoma
|
No biomarker
|
Pancreatic Adenocarcinoma
|
gemcitabine + albumin-bound paclitaxel Sensitive: A1 - Approval
|
gemcitabine + albumin-bound paclitaxel Sensitive: A1 - Approval
|
No biomarker
|
Pancreatic Adenocarcinoma
|
No biomarker
|
Pancreatic Adenocarcinoma
|
5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan Sensitive: A1 - Approval
|
5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan Sensitive: A1 - Approval
|
No biomarker
|
Pancreatic Cancer
|
No biomarker
|
Pancreatic Cancer
|
erlotinib Sensitive: A1 - Approval
|
erlotinib Sensitive: A1 - Approval
|
No biomarker
|
Pancreatic Cancer
|
No biomarker
|
Pancreatic Cancer
|
GEM-CAP Sensitive: A2 - Guideline
|
GEM-CAP Sensitive: A2 - Guideline
|
No biomarker
|
Pancreatic Adenocarcinoma
|
No biomarker
|
Pancreatic Adenocarcinoma
|
LV5FU2 Sensitive: A2 - Guideline
|
LV5FU2 Sensitive: A2 - Guideline
|
No biomarker
|
Pancreatic Adenocarcinoma
|
No biomarker
|
Pancreatic Adenocarcinoma
|
CAPOX Sensitive: A2 - Guideline
|
CAPOX Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Pancreatic Adenocarcinoma
|
NTRK3 fusion
|
Pancreatic Adenocarcinoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Pancreatic Adenocarcinoma
|
NTRK2 fusion
|
Pancreatic Adenocarcinoma
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
No biomarker
|
Pancreatic Cancer
|
No biomarker
|
Pancreatic Cancer
|
5-fluorouracil + nanoliposomal irinotecan Sensitive: A2 - Guideline
|
5-fluorouracil + nanoliposomal irinotecan Sensitive: A2 - Guideline
|
No biomarker
|
Pancreatic Cancer
|
No biomarker
|
Pancreatic Cancer
|
5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline
|
5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline
|
No biomarker
|
Pancreatic Cancer
|
No biomarker
|
Pancreatic Cancer
|
5-fluorouracil Sensitive: A2 - Guideline
|
5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Pancreatic Cancer
|
No biomarker
|
Pancreatic Cancer
|
5-fluorouracil + irinotecan Sensitive: A2 - Guideline
|
5-fluorouracil + irinotecan Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Pancreatic Adenocarcinoma
|
NTRK3 fusion
|
Pancreatic Adenocarcinoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
No biomarker
|
Pancreatic Cancer
|
No biomarker
|
Pancreatic Cancer
|
gemcitabine Sensitive: A2 - Guideline
|
gemcitabine Sensitive: A2 - Guideline
|
No biomarker
|
Pancreatic Adenocarcinoma
|
No biomarker
|
Pancreatic Adenocarcinoma
|
erlotinib Sensitive: A2 - Guideline
|
erlotinib Sensitive: A2 - Guideline
|
No biomarker
|
Pancreatic Adenocarcinoma
|
No biomarker
|
Pancreatic Adenocarcinoma
|
capecitabine Sensitive: A2 - Guideline
|
capecitabine Sensitive: A2 - Guideline
|
No biomarker
|
Pancreatic Adenocarcinoma
|
No biomarker
|
Pancreatic Adenocarcinoma
|
5-fluorouracil + capecitabine Sensitive: A2 - Guideline
|
5-fluorouracil + capecitabine Sensitive: A2 - Guideline
|
No biomarker
|
Pancreatic Adenocarcinoma
|
No biomarker
|
Pancreatic Adenocarcinoma
|
5-fluorouracil Sensitive: A2 - Guideline
|
5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Pancreatic Adenocarcinoma
|
No biomarker
|
Pancreatic Adenocarcinoma
|
gemcitabine Sensitive: A2 - Guideline
|
gemcitabine Sensitive: A2 - Guideline
|
No biomarker
|
Pancreatic Adenocarcinoma
|
No biomarker
|
Pancreatic Adenocarcinoma
|
gemcitabine + capecitabine Sensitive: A2 - Guideline
|
gemcitabine + capecitabine Sensitive: A2 - Guideline
|
BRCA1 mutation
|
Pancreatic Adenocarcinoma
|
BRCA1 mutation
|
Pancreatic Adenocarcinoma
|
cisplatin + gemcitabine Sensitive: A2 - Guideline
|
cisplatin + gemcitabine Sensitive: A2 - Guideline
|
BRCA2 mutation
|
Pancreatic Adenocarcinoma
|
BRCA2 mutation
|
Pancreatic Adenocarcinoma
|
cisplatin + gemcitabine Sensitive: A2 - Guideline
|
cisplatin + gemcitabine Sensitive: A2 - Guideline
|
PALB2 mutation
|
Pancreatic Adenocarcinoma
|
PALB2 mutation
|
Pancreatic Adenocarcinoma
|
cisplatin + gemcitabine Sensitive: A2 - Guideline
|
cisplatin + gemcitabine Sensitive: A2 - Guideline
|
No biomarker
|
Pancreatic Cancer
|
No biomarker
|
Pancreatic Cancer
|
FOLFIRINOX Sensitive: A2 - Guideline
|
FOLFIRINOX Sensitive: A2 - Guideline
|
No biomarker
|
Pancreatic Cancer
|
No biomarker
|
Pancreatic Cancer
|
gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline
|
gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Pancreatic Cancer
|
NTRK3 fusion
|
Pancreatic Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Pancreatic Cancer
|
NTRK2 fusion
|
Pancreatic Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Pancreatic Cancer
|
NTRK1 fusion
|
Pancreatic Cancer
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
NTRK3 fusion
|
Pancreatic Cancer
|
NTRK3 fusion
|
Pancreatic Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Pancreatic Cancer
|
NTRK2 fusion
|
Pancreatic Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Pancreatic Cancer
|
NTRK1 fusion
|
Pancreatic Cancer
|
larotrectinib Sensitive: A2 - Guideline
|
larotrectinib Sensitive: A2 - Guideline
|
No biomarker
|
Pancreatic Adenocarcinoma
|
No biomarker
|
Pancreatic Adenocarcinoma
|
5-fluorouracil + irinotecan Sensitive: A2 - Guideline
|
5-fluorouracil + irinotecan Sensitive: A2 - Guideline
|
NTRK1 fusion
|
Pancreatic Adenocarcinoma
|
NTRK1 fusion
|
Pancreatic Adenocarcinoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
MSI-H/dMMR
|
Pancreatic Adenocarcinoma
|
MSI-H/dMMR
|
Pancreatic Adenocarcinoma
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
NTRK2 fusion
|
Pancreatic Adenocarcinoma
|
NTRK2 fusion
|
Pancreatic Adenocarcinoma
|
entrectinib Sensitive: A2 - Guideline
|
entrectinib Sensitive: A2 - Guideline
|
No biomarker
|
Pancreatic Cancer
|
No biomarker
|
Pancreatic Cancer
|
FG-3019 Sensitive: B - Late Trials
|
FG-3019 Sensitive: B - Late Trials
|
No biomarker
|
Pancreatic Cancer
|
No biomarker
|
Pancreatic Cancer
|
capecitabine Sensitive: B - Late Trials
|
capecitabine Sensitive: B - Late Trials
|
No biomarker
|
Pancreatic Cancer
|
No biomarker
|
Pancreatic Cancer
|
devimistat Sensitive: B - Late Trials
|
devimistat Sensitive: B - Late Trials
|
TMB-H
|
Pancreatic Cancer
|
TMB-H
|
Pancreatic Cancer
|
pembrolizumab Sensitive: B - Late Trials
|
pembrolizumab Sensitive: B - Late Trials
|
No biomarker
|
Pancreatic Ductal Adenocarcinoma
|
No biomarker
|
Pancreatic Ductal Adenocarcinoma
|
SBP-101 Sensitive: B - Late Trials
|
SBP-101 Sensitive: B - Late Trials
|
TMB-H
|
Pancreatic Cancer
|
TMB-H
|
Pancreatic Cancer
|
PD1 inhibitor Sensitive: B - Late Trials
|
PD1 inhibitor Sensitive: B - Late Trials
|
ELAVL1 expression
|
Pancreatic Cancer
|
ELAVL1 expression
|
Pancreatic Cancer
|
NUC-3373 Sensitive: B - Late Trials
|
NUC-3373 Sensitive: B - Late Trials
|
No biomarker
|
Pancreatic Ductal Adenocarcinoma
|
No biomarker
|
Pancreatic Ductal Adenocarcinoma
|
gemcitabine Sensitive: B - Late Trials
|
gemcitabine Sensitive: B - Late Trials
|
No biomarker
|
Pancreatic Ductal Adenocarcinoma
|
No biomarker
|
Pancreatic Ductal Adenocarcinoma
|
gemcitabine + capecitabine Sensitive: B - Late Trials
|
gemcitabine + capecitabine Sensitive: B - Late Trials
|
No biomarker
|
Pancreatic Cancer
|
No biomarker
|
Pancreatic Cancer
|
FOLFIRINOX + GEM-CAP Sensitive: B - Late Trials
|
FOLFIRINOX + GEM-CAP Sensitive: B - Late Trials
|
No biomarker
|
Pancreatic Cancer
|
No biomarker
|
Pancreatic Cancer
|
TH 302 Sensitive: B - Late Trials
|
TH 302 Sensitive: B - Late Trials
|
CCL11 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
CCL11 overexpression
|
Pancreatic Ductal Adenocarcinoma
|
tertomotide Sensitive: B - Late Trials
|
tertomotide Sensitive: B - Late Trials
|
No biomarker
|
Pancreatic Cancer
|
No biomarker
|
Pancreatic Cancer
|
CORT125134 Sensitive: B - Late Trials
|
CORT125134 Sensitive: B - Late Trials
|
No biomarker
|
Pancreatic Ductal Adenocarcinoma
|
No biomarker
|
Pancreatic Ductal Adenocarcinoma
|
CEND-1 Sensitive: B - Late Trials
|
CEND-1 Sensitive: B - Late Trials
|
RET fusion
|
Pancreatic Cancer
|
RET fusion
|
Pancreatic Cancer
|
pralsetinib Sensitive: C1 - Off-label
|
pralsetinib Sensitive: C1 - Off-label
|
BRCA2 mutation
|
Pancreatic Cancer
|
BRCA2 mutation
|
Pancreatic Cancer
|
rucaparib Sensitive: C1 - Off-label
|
rucaparib Sensitive: C1 - Off-label
|
NTRK1 fusion
|
Pancreatic Adenocarcinoma
|
NTRK1 fusion
|
Pancreatic Adenocarcinoma
|
larotrectinib Sensitive: C1 - Off-label
|
larotrectinib Sensitive: C1 - Off-label
|
BRCA1 mutation
|
Pancreatic Cancer
|
BRCA1 mutation
|
Pancreatic Cancer
|
rucaparib Sensitive: C1 - Off-label
|
rucaparib Sensitive: C1 - Off-label
|
KRAS G12C
|
Pancreatic Cancer
|
KRAS G12C
|
Pancreatic Cancer
|
sotorasib Sensitive: C1 - Off-label
|
sotorasib Sensitive: C1 - Off-label
|
BRAF V600E
|
Pancreatic Cancer
|
BRAF V600E
|
Pancreatic Cancer
|
encorafenib + binimetinib Sensitive: C1 - Off-label
|
encorafenib + binimetinib Sensitive: C1 - Off-label
|
PD-L1 expression
|
Pancreatic Cancer
|
PD-L1 expression
|
Pancreatic Cancer
|
pembrolizumab Sensitive: C1 - Off-label
|
pembrolizumab Sensitive: C1 - Off-label
|
BRAF V600E
|
Pancreatic Cancer
|
BRAF V600E
|
Pancreatic Cancer
|
vemurafenib Sensitive: C1 - Off-label
|
vemurafenib Sensitive: C1 - Off-label
|
HER-2 overexpression
|
Pancreatic Cancer
|
HER-2 overexpression
|
Pancreatic Cancer
|
trastuzumab Sensitive: C1 - Off-label
|
trastuzumab Sensitive: C1 - Off-label
|
BRCA2 mutation
|
Pancreatic Ductal Adenocarcinoma
|
BRCA2 mutation
|
Pancreatic Ductal Adenocarcinoma
|
olaparib Sensitive: C1 - Off-label
|
olaparib Sensitive: C1 - Off-label
|
ATM mutation
|
Pancreatic Cancer
|
ATM mutation
|
Pancreatic Cancer
|
olaparib Sensitive: C1 - Off-label
|
olaparib Sensitive: C1 - Off-label
|
ATM mutation
|
Pancreatic Ductal Adenocarcinoma
|
ATM mutation
|
Pancreatic Ductal Adenocarcinoma
|
olaparib Sensitive: C1 - Off-label
|
olaparib Sensitive: C1 - Off-label
|
RET fusion
|
Pancreatic Adenocarcinoma
|
RET fusion
|
Pancreatic Adenocarcinoma
|
pralsetinib Sensitive: C1 - Off-label
|
pralsetinib Sensitive: C1 - Off-label
|
TMB-H
|
Pancreatic Adenocarcinoma
|
TMB-H
|
Pancreatic Adenocarcinoma
|
pembrolizumab Sensitive: C1 - Off-label
|
pembrolizumab Sensitive: C1 - Off-label
|
RET fusion
|
Pancreatic Cancer
|
RET fusion
|
Pancreatic Cancer
|
selpercatinib Sensitive: C1 - Off-label
|
selpercatinib Sensitive: C1 - Off-label
|
BRCA1 mutation
|
Pancreatic Ductal Adenocarcinoma
|
BRCA1 mutation
|
Pancreatic Ductal Adenocarcinoma
|
olaparib Sensitive: C1 - Off-label
|
olaparib Sensitive: C1 - Off-label
|
BRCA2 mutation
|
Pancreatic Cancer
|
BRCA2 mutation
|
Pancreatic Cancer
|
ABT-888 Sensitive: C2 – Inclusion Criteria
|
ABT-888 Sensitive: C2 – Inclusion Criteria
|
PALB2 mutation
|
Pancreatic Cancer
|
PALB2 mutation
|
Pancreatic Cancer
|
ABT-888 Sensitive: C2 – Inclusion Criteria
|
ABT-888 Sensitive: C2 – Inclusion Criteria
|
BRCA1 mutation
|
Pancreatic Cancer
|
BRCA1 mutation
|
Pancreatic Cancer
|
ABT-888 Sensitive: C2 – Inclusion Criteria
|
ABT-888 Sensitive: C2 – Inclusion Criteria
|
PALB2 mutation
|
Pancreatic Cancer
|
PALB2 mutation
|
Pancreatic Cancer
|
rucaparib Sensitive: C2 – Inclusion Criteria
|
rucaparib Sensitive: C2 – Inclusion Criteria
|
NRAS mutation
|
Pancreatic Cancer
|
NRAS mutation
|
Pancreatic Cancer
|
avelumab Sensitive: C2 – Inclusion Criteria
|
avelumab Sensitive: C2 – Inclusion Criteria
|
KRAS mutation
|
Pancreatic Cancer
|
KRAS mutation
|
Pancreatic Cancer
|
avelumab Sensitive: C2 – Inclusion Criteria
|
avelumab Sensitive: C2 – Inclusion Criteria
|
NRG1 fusion
|
Pancreatic Cancer
|
NRG1 fusion
|
Pancreatic Cancer
|
MCLA-128 Sensitive: C2 – Inclusion Criteria
|
MCLA-128 Sensitive: C2 – Inclusion Criteria
|
KRAS mutation
|
Pancreatic Ductal Adenocarcinoma
|
KRAS mutation
|
Pancreatic Ductal Adenocarcinoma
|
pembrolizumab + trametinib Sensitive: C2 – Inclusion Criteria
|
pembrolizumab + trametinib Sensitive: C2 – Inclusion Criteria
|
TP53 mutation
|
Pancreatic Cancer
|
TP53 mutation
|
Pancreatic Cancer
|
gemcitabine + albumin-bound paclitaxel Sensitive: C3 – Early Trials
|
gemcitabine + albumin-bound paclitaxel Sensitive: C3 – Early Trials
|
HGF-H
|
Pancreatic Ductal Adenocarcinoma
|
HGF-H
|
Pancreatic Ductal Adenocarcinoma
|
FOLFIRINOX Resistant: C3 – Early Trials
|
FOLFIRINOX Resistant: C3 – Early Trials
|
MSI-L/dMMR
|
Pancreatic Ductal Adenocarcinoma
|
MSI-L/dMMR
|
Pancreatic Ductal Adenocarcinoma
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
MSI-L/dMMR
|
Pancreatic Ductal Adenocarcinoma
|
MSI-L/dMMR
|
Pancreatic Ductal Adenocarcinoma
|
ipilimumab Sensitive: C3 – Early Trials
|
ipilimumab Sensitive: C3 – Early Trials
|
MSI-L/dMMR
|
Pancreatic Ductal Adenocarcinoma
|
MSI-L/dMMR
|
Pancreatic Ductal Adenocarcinoma
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
KRAS G12R
|
Pancreatic Adenocarcinoma
|
KRAS G12R
|
Pancreatic Adenocarcinoma
|
selumetinib Sensitive: C3 – Early Trials
|
selumetinib Sensitive: C3 – Early Trials
|
UGT1A1*28 + UGT1A1*6
|
Pancreatic Cancer
|
UGT1A1*28 + UGT1A1*6
|
Pancreatic Cancer
|
FOLFIRINOX Sensitive: C3 – Early Trials
|
FOLFIRINOX Sensitive: C3 – Early Trials
|
KRAS exon 2 mutation
|
Pancreatic Cancer
|
KRAS exon 2 mutation
|
Pancreatic Cancer
|
erlotinib Resistant: C3 – Early Trials
|
erlotinib Resistant: C3 – Early Trials
|
EPHB4 expression
|
Pancreatic Cancer
|
EPHB4 expression
|
Pancreatic Cancer
|
gemcitabine + albumin-bound paclitaxel Sensitive: C3 – Early Trials
|
gemcitabine + albumin-bound paclitaxel Sensitive: C3 – Early Trials
|
KRAS G12R
|
Pancreatic Cancer
|
KRAS G12R
|
Pancreatic Cancer
|
cobimetinib Sensitive: C3 – Early Trials
|
cobimetinib Sensitive: C3 – Early Trials
|
KRAS mutation
|
Pancreatic Adenocarcinoma
|
KRAS mutation
|
Pancreatic Adenocarcinoma
|
trametinib Sensitive: C3 – Early Trials
|
trametinib Sensitive: C3 – Early Trials
|
PALB2 mutation
|
Pancreatic Ductal Adenocarcinoma
|
PALB2 mutation
|
Pancreatic Ductal Adenocarcinoma
|
FOLFIRINOX Sensitive: C3 – Early Trials
|
FOLFIRINOX Sensitive: C3 – Early Trials
|
BRCA1 mutation + BRCA2 mutation
|
Pancreatic Ductal Adenocarcinoma
|
BRCA1 mutation + BRCA2 mutation
|
Pancreatic Ductal Adenocarcinoma
|
FOLFIRINOX Sensitive: C3 – Early Trials
|
FOLFIRINOX Sensitive: C3 – Early Trials
|
FANCF mutation
|
Pancreatic Ductal Adenocarcinoma
|
FANCF mutation
|
Pancreatic Ductal Adenocarcinoma
|
FOLFIRINOX Sensitive: C3 – Early Trials
|
FOLFIRINOX Sensitive: C3 – Early Trials
|
MSH2 mutation
|
Pancreatic Ductal Adenocarcinoma
|
MSH2 mutation
|
Pancreatic Ductal Adenocarcinoma
|
FOLFIRINOX Sensitive: C3 – Early Trials
|
FOLFIRINOX Sensitive: C3 – Early Trials
|
BRCA2 mutation
|
Pancreatic Ductal Adenocarcinoma
|
BRCA2 mutation
|
Pancreatic Ductal Adenocarcinoma
|
FOLFIRINOX Sensitive: C3 – Early Trials
|
FOLFIRINOX Sensitive: C3 – Early Trials
|
BRCA1 mutation
|
Pancreatic Ductal Adenocarcinoma
|
BRCA1 mutation
|
Pancreatic Ductal Adenocarcinoma
|
FOLFIRINOX Sensitive: C3 – Early Trials
|
FOLFIRINOX Sensitive: C3 – Early Trials
|
